


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Dasatinib. [Updated 2018 Dec 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



# Dasatinib

Revised: December 3, 2018.

CASRN: 302962-49-8



## **Drug Levels and Effects**

## Summary of Use during Lactation

Although one breastfed infants apparently experienced no adverse effects during maternal use of dasatinib, no long-term data are available. Because dasatinib and its metabolite are more than 90% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with dasatinib during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during dasatinib therapy and for 2 weeks after the last dose.

## **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Infant Levels. Relevant published information was not found as of the revision date.

### **Effects in Breastfed Infants**

A woman with chronic myeloid leukemia received dasatinib 100 mg daily throughout pregnancy and continuing postpartum, apparently while breastfeeding her infant (extent not stated). No adverse reactions were reported in her infant.[1]

#### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

#### **Alternate Drugs to Consider**

Imatinib

#### References

1. Alizadeh H, Jaafar H, Kajtar B. Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: Follow-up of the case with a review of published reports. Ann Saudi Med. 2015;35:468-71. PubMed PMID: 26657232.

## **Substance Identification**

#### **Substance Name**

Dasatinib

### **CAS Registry Number**

302962-49-8

#### **Drug Class**

Breast Feeding

Lactation

Antineoplastic Agents

**Enzyme Inhibitors** 

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors